Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China) Stock code: 2120

INSIDE INFORMATION APPLICATION FOR THE FULL CIRCULATION OF SHARES BY THE COMPANY

This announcement is made by Wenzhou Kangning Hospital Co., Ltd. (the "Company") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and Part XIVA of the Securities and Futures Ordinance.

References are made to the China Securities Regulatory Commission (the "CSRC") Announcement [2019] No. 22 "Guidelines on Application for 'Full Circulation' of Domestic Unlisted Shares of H-share Companies"《(H股公司境內未上市股份申請"全流通"業務指引》) issued by the CSRC on November 14, 2019 and amended on August 10, 2023 and the "Trial Administrative Measures for Overseas Securities Offering and Listing by Domestic Companies"《(境內企業境外發行證券和上市管理試行辦法》) issued on February 17, 2023 regarding the guidelines for procedures to apply for full circulation of shares by companies whose H shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The board of directors (the "Board") of the Company is pleased to announce that the Company has submitted an application (the "Application") to the CSRC as of the date of this announcement in respect of the conversion of 9,286,359 domestic shares (the "Unlisted Shares") into H shares (the "H Shares") of the Company. Subject to obtaining all the fillings and/or approvals from relevant regulatory authorities (including but not limited to the CSRC and the Stock Exchange) and the compliance with all the applicable laws and regulations, such Unlisted Shares shall be converted into H Shares and be eligible to be listed and traded on the Main Board of the Stock Exchange, details of which are as follows:

Name of shareholders	Number of domestic shares to be converted into H Shares	to the Company's total issued
Shanghai Tanying Investment L.P.		
(上海檀英投資合夥企業(有限合夥))	4,519,003	6.25%
CITIC Securities Investment Limited		
(中信証券投資有限公司)	2,780,000	3.84%
Shanghai Qiangang Investment Management Partnership L.P.		
(上海乾剛投資管理合夥企業(有限合夥))	1,327,361	1.83%
HOU Minghua (侯明華)	460,462	0.64%
YUAN Boyin (袁伯銀)	153,487	0.21%
Shanghai Yongpei Heng Enterprise Management Co., Ltd.		
(上海永佩珩企業管理有限公司)	46,046	0.06%
Total	9,286,359	12.83%

As of the date of this announcement, the Company has not completed the filing with the CSRC in respect of the Application. Further announcement(s) will be made on the progress and details of the Application as and when appropriate.

The full circulation and the conversion and listing of the shares are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC August 21, 2025

As of the date of this announcement, the Company's executive Directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive Directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive Directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. CHAN Sai Keung Hugo.